China SXT Pharmaceuticals (SXTC) Equity Average (2018 - 2025)
China SXT Pharmaceuticals has reported Equity Average over the past 8 years, most recently at $17.8 million for Q3 2025.
- For Q3 2025, Equity Average rose 23.16% year-over-year to $17.8 million; the TTM value through Sep 2025 reached $17.8 million, up 23.16%, while the annual FY2025 figure was $14.7 million, 2.62% up from the prior year.
- Equity Average for Q3 2025 was $17.8 million at China SXT Pharmaceuticals, up from $15.2 million in the prior quarter.
- Over five years, Equity Average peaked at $17.8 million in Q3 2025 and troughed at $9.5 million in Q1 2024.
- A 5-year average of $14.4 million and a median of $14.9 million in 2021 define the central range for Equity Average.
- Biggest five-year swings in Equity Average: surged 65.7% in 2021 and later plummeted 36.18% in 2023.
- Year by year, Equity Average stood at $14.9 million in 2021, then grew by 4.1% to $15.5 million in 2022, then plummeted by 36.18% to $9.9 million in 2023, then skyrocketed by 46.53% to $14.5 million in 2024, then grew by 23.16% to $17.8 million in 2025.
- Business Quant data shows Equity Average for SXTC at $17.8 million in Q3 2025, $15.2 million in Q1 2025, and $14.5 million in Q3 2024.